Maze Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Net Income	-120.8	52.23	-100.42	-114.94
Depreciation & Amortization	2.83	3.3	4.09	3.82
Loss (Gain) From Sale of Investments	-	-	-	2.4
Loss (Gain) on Equity Investments	-	-	-	3.54
Stock-Based Compensation	11.66	9.65	8.75	6.74
Other Operating Activities	7.75	12.3	7.07	2.48
Change in Accounts Payable	1.5	-0.2	0.4	-3.78
Change in Other Net Operating Assets	-8.16	-1.32	-6.72	0.54
Operating Cash Flow	-105.23	75.95	-86.83	-99.2
Capital Expenditures	-1.4	-1.15	-0.44	-1.97
Investment in Securities	-	-	-	-1.2
Investing Cash Flow	-1.4	-1.15	-0.44	-3.17
Long-Term Debt Issued	-	24.48	16.18	-
Net Debt Issued (Repaid)	-	24.48	16.18	-
Issuance of Common Stock	128.78	0.73	0.21	0.15
Other Financing Activities	-3.47	-3.15	-	-
Financing Cash Flow	196.1	92.85	16.39	1.73
Net Cash Flow	89.48	167.65	-70.88	-100.65
Free Cash Flow	-106.63	74.81	-87.27	-101.17
Free Cash Flow Margin	-4265.00%	44.66%	-	-
Free Cash Flow Per Share	-5.51	27.40	-38.14	-50.33
Cash Income Tax Paid	1.23	1.23	-	-
Levered Free Cash Flow	-69.69	52.09	-52.55	-
Unlevered Free Cash Flow	-69.69	52.09	-52.55	-
Change in Working Capital	-6.66	-1.52	-6.32	-3.24

Updated Aug 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q